Clinical Trial: IMU-838 in Adults with Progressive MS

Funding:

Immunic AG

Description

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy, safety, and tolerability of IMU-838 in people between 18 and 65 years old with primary or secondary progressive multiple sclerosis. Participants will be randomly assigned to receive either IMU-838 (vidofludimus calcium) or an inactive placebo as oral tablets once daily for 120 weeks, and continue to receive IMU-838 (vidofludimus calcium) up to approximately 8 years. During the main treatment period each individual will be invited for in-person visits every 12 weeks for study assessments, blood test, MRI control and study drug dispensation. 

Study Site Contact List
Alvares Enrique
Sarah Busano
Denver, CO
sarah.bausano@cuanschutz.edu
303.724.3021 
 
Scott James
Deborah Hrusa 
Daytona Beach, FL
dhrusa@naobresearch.com
386 676 6340
 
Karilao Sonia
Maria Anaya 
Fort Lauderdale, FL
manaya@NeuroFL.com 
954-530-5844  
 
Wynn Daniel
Anelia Vassileva
Chicago, IL
research4@cinltd.com 
847 – 509 - 0272 
 
Cerghet Mirela  
Kathryn Swiftney
Detroit, MI
kswiftn1@hfhs.org 
+ 313-916-3501 
 
Baker Mathew
Jackie Brady 
Naples, FL
jackie@aqualaneresearch.com
 
Ford Corey 
Prince Thomas 
Albuquerque, NM
prthomas@salud.unm.edu
505-272-8905 
 
Backer Daniel
Katharine Russman 
Baltimore, MD
Russmank@inirehab.com
410-828-4629 ext. 108 
 
Mehta Bijal
Guillermo Castro 
Los Angeles, CA
guillermo.castro@lundquist.org
(424)571-7625 
 
Myers Bennett
Allison Emborsky 
Buffalo, NY
AEmborsky@DENTINSTITUTE.COM
716-558-3543 
 
 
Boster Aaron
Tosha Heineman 
Columbus, OH
tosha.heineman@bosterms.com 
614-826-1298 
 
Sharlin Kenneth
Shawna Tindall 
Springfield, MO
shawna@sharlinfxmed.com
 417-485-4330 ext. 1005